About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Financial Performance - Mirion's Q1 2025 revenue reached $202 million, reflecting a 49% total increase and a 60% organic growth compared to Q1 2024[10, 19] - Adjusted EBITDA for Q1 2025 was $467 million, an 182% increase from Q1 2024, with a margin expansion of 260 bps[9, 10] - Adjusted EPS increased by 667% to $010 in Q1 2025 from $006 in Q1 2024[22] - Adjusted Free Cash Flow for Q1 2025 was $29 million, a significant improvement compared to previous years[9, 39] Orders and Backlog - Strong Q1 orders with an 115% increase compared to Q1 2024, indicating consistent demand[9, 10] - The company repurchased 116 million shares in Q1 2025 as part of its capital deployment strategy[11] - Backlog trend shows a slight decrease of 1% vs adjusted Q1 2024, reaching $814 million in Q1 2025[48] Segment Performance - Nuclear & Safety segment revenue grew by 60% in Q1 2025, with organic growth of 76%[25] - Medical segment revenue increased by 27% in Q1 2025, with organic growth of 30%[32] Guidance and Outlook - The company reaffirms its 2025 guidance for Organic Revenue Growth (55% - 75%), Adjusted EBITDA ($215 - $230 million), Adjusted FCF, and Adjusted EPS[41]